Common Ground On Pricing And Access
This article was originally published in RPM Report
Executive Summary
The head of CMS wants the biopharma industry to work collaboratively to address concerns about drug pricing. The following remarks were prepared for delivery during the Biopharma Congress on November 12. The event was co-hosted by Prevision Policy and Friends of Cancer Research